Clearside’s long-acting eye project shows promise

The wet age-related macular degeneration market is dominated by Regeneron and Bayer’s monthly injection Eylea, but other groups are trying to get a piece of the action by developing longer-lasting options. Clearside Medical is the latest to join the pack, with promising phase 1 data on CLS-AX sending the company’s stock up 38% yesterday.